Press Releases
- First patient dosed in the amended HO172 clinical study of tasquinimod in myelofibrosis
- Number of shares and votes in Active Biotech
- Active Biotech announces timetable for reverse share split
- Annual General Meeting of Active Biotech AB
- European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON